Home > Archive > 2016 >

Volume 35, Number 3 (July/August)

How to Choose Diabetes Drugs Wisely (pages 10-15)

Elena A. Christofides, M.D., FACE CEO/Owner, Endocrinology Associates, Inc. Adjunct Assistant Professor and Clinical Associate Professor, Ohio State University College of Medicine

In recent years, the conversation around diabetes management has become a cacophony of choices. The medication landscape has grown exponentially in the past 10 years with the introduction of more than a dozen new products and half a dozen new insulins.
Drug treatment

SGLT-2 Inhibitors and Glucose Homeostasis (pages 16-19)

Kathleen Wyne, M.D., Ph.D.

The role of the kidney in glucose homeostasis had been ignored for many years, because studies to evaluate insulin resistance and beta-cell function focused on the liver and muscle. Even when unexplained hypoglycemia occurred as the presentation of renal failure, it was attributed to the prolonged half life of insulin in the setting of diabetic nephropathy. However, once studies began to look at the kidney, gluconeogenesis by the kidney was found to play an important role in preventing hypoglycemia. In fact, the kidney contributes to glucose homeostasis through multiple processes, including gluconeogenesis, glucose filtration, glucose reabsorption and glucose consumption.
Drug treatmentSodium-glucose cotransporter 2 inhibitors

Journal Watch (pages 20-23)

This column highlights recent clinical trial data and landmark clinical trials to provide readers with relevant information and links for obtaining clinical trial data and articles to facilitate discussion with patients and other providers. It features the results of four clinical trials: WHO Global Report on Diabetes SUSTAIN1: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects with Type 2 Diabetes LIRA-SWITCH™: Efficacy and Safety of Switching from Sitagliptin to Liraglutide in Subjects with Type 2 Diabetes Not Achieving Adequate Glycemic Control on Sitagliptin and Metformin Real-world Evidence Comparing an SGLT2 Inhibitor with DPP-4 Inhibitors
Clinical trials

Commentary: Diabetes-Related Bills in the 114th Congress (pages 24-30)

Kathleen Wyne, M.D., Ph.D.

This article discusses the current bills under review in the U.S. Congress, so that when your patients express frustrations over difficulties in obtaining supplies, you can not only “suggest you call your congressman,” but also provide them with specific details of how to determine who to call and what specific bill to reference.
Health services and insurance